Industry: 'Learn From COVID And Cut EU Drug Review Times'
Change Could Help In Reimbursement And Access Decisions
A report commissioned by the European pharmaceutical industry body EFPIA has come up with some suggestions for reducing the time the European Commission takes to issue marketing authorizations for cancer drugs – and possibly other products too.
